New Antipsychotic Medications in the Last Decade

[1] McCormack PL(2015)Cariprazine: first global approval Drugs 75 2035-2043

[2] Seneca N(2011)Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography Psychopharmacology 218 579-587

[3] Finnema SJ(2013)Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C] cariprazine: an in vivo positron emission tomography study in nonhuman primates Synapse 67 258-264

[4] Laszlovszky I(2016)Mechanism of action of cariprazine CNS Spectr 21 123-127

[5] Kiss B(2010)Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile J Pharmacol Exp Ther 333 328-340

[6] Horvath A(2012)Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors Bioorg Med Chem Lett 22 3437-3440

[7] Pasztor G(2016)Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment) Drug Des Devel Ther 10 327-338

[8] Toth M(2015)Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial J Clin Psychiatry 76 e1574-e1582

[9] Varrone A(2016)Cariprazine in the treatment of schizophrenia: a proof-of-concept trial Int Clin Psychopharmacol 31 61-68

[10] Steiger C(2014)An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial Schizophr Res 152 450-457

[1] McCormack PL(2015)Cariprazine: first global approval Drugs 75 2035-2043

[2] Seneca N(2011)Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography Psychopharmacology 218 579-587

[3] Finnema SJ(2013)Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C] cariprazine: an in vivo positron emission tomography study in nonhuman primates Synapse 67 258-264

[4] Laszlovszky I(2016)Mechanism of action of cariprazine CNS Spectr 21 123-127

[5] Kiss B(2010)Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile J Pharmacol Exp Ther 333 328-340

[6] Horvath A(2012)Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors Bioorg Med Chem Lett 22 3437-3440

[7] Pasztor G(2016)Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment) Drug Des Devel Ther 10 327-338

[8] Toth M(2015)Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial J Clin Psychiatry 76 e1574-e1582

[9] Varrone A(2016)Cariprazine in the treatment of schizophrenia: a proof-of-concept trial Int Clin Psychopharmacol 31 61-68

[10] Steiger C(2014)An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial Schizophr Res 152 450-457